Company* (Symbol)**

Funding Institution

Amount (M)

Type

Details (Date)

Aastrom Biosciences Inc. (ASTM)

National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH)

ND

Phase I Small Business Innovation Research (SBIR) grant

Aastrom will use the grant to support the development of processes for ex vivo antigen-specific T-lymphocytes (T-cells) production (11/99)

Acorda Therapeutics Inc.*

NIH

$0.1

Phase I Small Business Technology Transfer (STTR) grant

Acorda and Martin Grumet, of the New York University Medical Center, will use the grant to fund collaborative research to synthesize fragments of a protein, L1, to test its ability to promote neurite outgrowth in culture (9/99)

Albany Molecular Research Inc. (AMRI)

National Institute on Drug Abuse (NIDA) of the NIH

$0.1

SBIR grant

Albany will use the grant to further develop a compound in the iboga alkaloid family, 18-methoxycoronaridine, as a potential drug abuse therapeutic (10/99)

Akkadix Corp.*

National Institute of General Medical Sciences at the NIH

$0.8 grant

Phase II SBIR

Akkadix will use the grant to develop high-throughput computational approaches to improve the accuracy of automated methods that predict protein functions (10/99)

Ambion Inc.*

NIAID

$0.8

Phase II SBIR

Ambion will use the grant to further the development of its Armored RNA technology (10/99)

Ronald H. Goldfarb of Angstrom Pharmaceuticals Inc.*

State of Texas Advanced Technology Program

ND

Research grant

Goldfarb was awarded a grant to study new antimetastatic therapy through the combined use of Angstrom's drug, A6, with cyclophosphamide (12/99)

Avant Immunotherapeutics Inc. (AVAN)

United States Small Business Administration

ND

Tibbetts Award

Avant received a Tibbetts award in recognition of its accomplishments using SBIR grant funds (10/99)

Aurora Biosciences Corp. (ABSC)

Cystic Fibrosis Foundation (CFF)

ND

Research grant

As part of its Therapeutics Development Program, the CFF provided funding for a collaboration with Aurora to identify potential therapeutics to treat the defect identified as the primary cause of cystic fibrosis (9/99)

BBI BioSeq (a subsidiary of Boston Biomedica Inc.; BBII)

National Heart Lung and Blood Institute of the NIH

ND

Phase I SBIR grant

BBI will use the six-month award to support development efforts in its pressure cycling technology for the inactivation of harmful bacteria (10/99)

Boston Life Sciences Inc.'s collaborating scientist, Larry Benowitz

Christopher Reeve Paralysis Foundation

ND

Research grant

Benowitz received a grant to support his research in axonal regeneration in the corticospinal tract using Inosine, a naturally-occurring small molecule licensed to Boston Life Sciences by Children's Hospital in Boston (11/99)

Cell Based Delivery Inc.*

National Institute of Aging of the NIH

$0.7

Phase II SBIR grant

Cell Based Delivery will use the two-year grant to fund development of its protein-secreting bioartificial muscle products (12/99)

Cellegy Pharmaceuticals Inc. (CLGY)

NIH

$0.1

SBIR grant

Cellegy will use the grant to investigate new treatments for anorectal disorders (10/99)

Cerus Corp. (CERS)

NIH

$0.8

Research grant

The grant will provide Cerus funding over a three-year period for preclinical research relating to the use of its proprietary technologies in conjunction with bone marrow transplantation as a treatment for blood disorders such as sickle cell anemia and thalassemia (10/99)

Corvas International Inc. (CVAS)

NIAID

$0.6

Phase I SBIR

Corvas will use the grant to support the discovery of protease inhibitors for prophylaxis and treatment of malaria (9/99)

Cubist Pharmaceuticals Inc. (CBST)

NIAID

$1.25

SBIR grants

Cubist was awarded three SBIR grants totaling $1.25M to support programs focused on the discovery of novel classes of anti-infective compounds for the treatment of life-threatening infections caused by microorganisms (10/99)

3-Dimensional Pharmaceuticals Inc.

NIH

$0.3

SBIR grants

3-Dimensional received two SBIR grants totaling $0.257 to support its research to crystallize and determine high-resolution 3D structures of G-protein coupled receptors (9/99)

Diversa Corp.*

NIH

$1.5

Phase II SBIR grants

Diversa received two Phase II SBIR grants totaling $1.5M; the company will use the grants to advance its drug discovery platform (9/99)

DrugAbuse Sciences Inc.*

NIDA

$0.95

Phase I SBIR and Phase II SBIR grants

DrugAbuse received two SBIR grants totaling $0.95M for the development of an improved treatment for drug abuse (11/99)

Echelon Research Laboratories Inc.*

United States Small Business Administration

ND

Tibbetts Award

Echelon received a Tibbetts award in recognition of its accomplishments using SBIR grant funds (10/99)

Eukarion Inc.*

National Cancer Institute

$0.85

Fast Track Small SBIR grant

Eukarion will use the grant for the development of EUK-189, a small molecule synthetic catalytic scavenger drug (11/99)

Genentech Inc. (NYSE: DNA) and Idec Pharmaceuticals Corp. (IDPH)

Cure for Lymphoma Foundation

ND

1999 Trailblazers Award

Genentech and Idec received the award in recognition of their research and development of Rituxan, a single-agent monotherapy for non-Hodgkin's lymphoma (11/99)

GeneTrace Systems Inc.*

National Institute of Standards and Technology (NIST)

$2

Advanced Technology Program grant

GeneTrace will use the grant to support development of a rapid, low-cost automated assay that can monitor the the production levels and activity of large numbers of proteins simultaneously (10/99)

Genome Therapeutics Corp. (GENE)

National Human Genome Research Institute

$12.9

Research grant

Genome Therapeutics will receive $12.9M in funding over the next three years for work conducted at the GTC Sequencing Center (10/99)

Idun Pharmaceuticals*

NIH

$0.9

Phase I SBIR grant

Idun will use the grant to advance its research of apoptosis inhibitors that extend the function and storage life of granulocytes (9/99)

Immunomedics Inc. (IMMU)

NIH

$1.07

Research grants

Immunomedics was awarded four research grants totaling $1.07M; the largest grant of $0.75M will support the development of a therapeutic for metastatic breast cancer; remaining grant funds will be used to develop a bacterial expression system for producing a ribonuclease to bring about rapid cell death in cancer cells, and for the development of a single-chain antibody fragment bearing the ribonuclease molecule as an immunotoxin fusion protein (9/99)

Ixion Biotechnology*

NIH

$0.2

Exploratory/Development grant

NIH awarded Ixion a two-year grant to further the company's research efforts on its novel approach that involves regenerating functional islet-like clusters in vitro using islet-producing stem cells derived from adult pancreases (10/99)

LigoCyte Pharmaceuticals*

Department of Defense

$1.5

Research grant

LigoCyte received $1.5M in federal funding to fund its bio-adhesion research that seeks to identify and prepare to deal with infectious agents and their toxins in the environment, including E. coli, the Norwalk virus and brucellosis (10/99)

MandalMed Inc.*

NIH

ND

Phase I SBIR and Phase I STTR

MandalMed will use the STTR in the development of new methods for cellular delivery of protein pharmaceuticals; the SBIR will be used to develop galectin-1 as a therapeutic for multiple sclerosis (11/99)

Maxygen Inc. (MAXY)

Defense Advanced Research Agency (DARPA)

$6.7

Research grant

Maxygen received a three-year grant from DARPA to use its MolecularBreeding directed evolution technology (DNA shuffling) to develop aerosol-based vaccines against a broad spectrum of pathogens (9/99)

MetaPhore Pharmaceuticals Inc.*

Department of Health and Human Services

$1.2

Phase I and Phase II SBIR grants

MetaPhore received two SBIR grants for the discovery and development of novel chelation and metal-based therapeutics for the treatment of iron overload diseases, and for the discovery of metal-based antibiotics for the treatment of tuberculosis (12/99)

MitoKor*

UC BioSTAR

ND

Research and development grant

MitoKor will partner with the University of California regents and the state of California through the UC BioSTAR project on a major grant to develop a mouse model for mitochondrial diseases (10/99)

Nanoprobes Inc.*

National Institute of General Medical Sciences (NIGMS) of the NIH

$0.1

Phase I SBIR grant

NIGMS awarded Phase I of a second fast-track SBIR grant to Nanoprobes to develop large, covalently linkable gold particles as alternatives to colloidal gold probes for use in microscopy and immunoassays (10/99)

National Center for Genome Resources

Rose-Legett Foundation

$0.25

Research grant

The Rose-Legett Foundation awarded the center a grant to establish a multi-year research program in gene expression; the program will comprise a database and software tools to help scientists analyze and better understand gene expression (9/99)

Novogen Inc. (Australia; NVGN)

Australian Department of Industry, Science and Resources

$2.5

Research and development grant

Novogen will use the grant to assist in the development of its cardiovascular drug, NV-04; the grant was awarded as part of the R&D START program sponsored by the Department of Industry, Science and Resources (10/99)

Pentose Pharmaceuticals Inc.*

National Heart, Lung and Blood Institute of the NIH

$0.1

SBIR grant

Pentose will use the grant to support the development of Inactine compounds for the elimination of viruses in red blood cell concentrates used for transfusion (10/99)

Pharming Group NV (AEX, EASDAQ:PHAR)

Netherlands and Finland governments

Euro6 (US$6.03)

Research and development grants

Pharming will use the government grants to support development programs of recombinant human Lactoferrin (9/99)

Phylos Inc.*

National Cancer Institute

$0.5

SBIR grant

Phylos will use the grant to support the evaluation of protein scaffolds for the design of anticancer agents (9/99)

NIAID

$0.6

SBIR grant

Phylos will use the grant to support the development of its PROfile chip, an addressable array of proteins that will have potential applications in proteomics (9/99)

PPL Therapeutics*

NIST

$2

Advanced Technology Program award

PPL will use the award to fund a three year research program for reducing the risk of rapid rejection of pig organs when transplanted into humans (10/99)

Proteome Inc.*

NIAID

$1.1

Phase II SBIR grant

Proteome will use the grant to support the production of curated proteome databases for major human fungal pathogens, as well as fungal model organisms (10/99)

Reprogenesis Inc.*

NIST

$2

Advanced Technology Program award

Reprogenesis will use the award to support the development of its cardiovascular biology program (10/99)

Salus Therapeutics Inc.*

National Institute of Neurological Disorders and Stroke of the NIH

$0.1

Phase I SBIR grant

Salus will use the grant to support its multiple sclerosis drug discovery program (10/99)

Sangamo Biosciences Inc.*

United States Department of Agriculture

ND

Research grant

SeQuel Genetics Inc.

Pittsburgh Biomedical Development Corp.

$0.05

Research grant

SeQuel will use the grant for costs associated with business organization and development related to its MegaSeQ technology to discover and monitor DNA mutations (9/99)

Theratechnologies Inc. (Canada; TSE:TH)

Technology Partnerships Canada

C$4.6 (US$3.13)

Research award

Theratechnologies will use the award to accelerate clinical development and commercialization of its photodynamic cancer treatment (11/99)

Therion Biologics Corp.*

NIAID

$1.5

Research contracts

Therion was awarded three contracts totaling $1.5M by the NIAID for the development and manufacture of novel AIDS vaccines and related research reagents (11/99)

Tissue Engineering Inc.*

NIH

$0.75

Phase II SBIR grant

Tissue Engineering will use the grant to expand its technology for developing collagen scaffolds for skin and wound healing (9/99)

Titan Pharmaceuticals Inc.

National Institute of Neurological Disorders and Stroke

$0.1

Phase I/II Fast Track SBIR grant

Titan will use the grant to support the development of its Spheramine therapy for Parkinson's disease (10/99)

Zen-Bio*

NIH

$0.1

SBIR grant

Zen-Bio will use the grant to investigate the use of adipose-derived stromal cells for the treatment of bone disorders (10/99)

TOTAL: $70.32M

Notes:

# This chart covers grants and awards to biotechnology companies, and university laboratories collaborating with biotechnology companies.

* Indicates a privately held company

** Unless otherwise indicated, symbols listed are on the Nasdaq market.

ND = Not Disclosed